個人化醫療市場規模、佔有率和成長分析（按產品、技術、給藥途徑、應用、最終用戶和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球個人化醫療市場規模將達到 5,604.9 億美元，到 2025 年將成長至 6,126.2 億美元，到 2033 年將成長至 1,2478.1 億美元，預測期（2026-2033 年）的複合成長率為 9.3%。

隨著基因技術被整合到個人化醫療中，為每位患者提供最佳治療方案，個人化醫療市場正經歷顯著成長。由於人類基因組的獨特性，疾病表現因人而異，這推動了對個人化診斷和治療的需求，尤其是在腫瘤領域。然而，基因技術的快速發展也引發了人們對腫瘤以外應用領域的興趣激增。該領域的投資持續成長，推動著創新，增強了個人化醫療在罕見疾病治療方面的潛力。目前，針對阿茲海默症和帕金森氏症等疾病的個人化治療方案的研究正在不斷深入。隨著醫療保健預算的增加以及製藥公司與政府機構之間合作的加強，對個人化醫療的需求預計將進一步加速成長。

全球個人化醫療市場促進因素

全球個人化醫療市場主要受基因技術的快速發展所驅動，基因技術正在革新醫療保健和製藥產業。基因技術估值不斷攀升，目前已超過50億美元，顯示市場需求強勁，並吸引大量投資。隨著技術的不斷進步，預計該市場將迎來顯著成長，年複合成長率（CAGR）將超過20%。基因技術的快速發展將提高個人化醫療的可近性和需求，從而促進全球患者更廣泛地採用和實施量身定做的醫療保健解決方案。

全球個人化醫療市場阻礙因素

儘管全球醫療基礎設施不斷進步，但相關成本卻持續攀升，而這部分經濟負擔往往最終轉嫁到消費者身上。在許多地區，醫療成本的成長速度超過了通貨膨脹率，導致對昂貴的個人化藥物的需求下降。這一趨勢對全球個人化藥物市場構成了重大挑戰，因為高昂的價格可能會阻礙人們投資這些創新療法。因此，患者面臨的經濟困境阻礙了市場成長，並限制了他們獲得可能挽救生命的個人化療法的機會，這成為該領域發展的主要阻礙因素。

全球個人化醫療市場趨勢

全球個人化醫療市場正經歷顯著變革，尤其是在新興經濟體，醫療保險覆蓋範圍的擴大是推動這項變革的主要動力。隨著越來越多的保險公司將這些先進療法納入保單，個人化療法的可近性和可負擔性也隨之提高。保險覆蓋範圍的擴大使更多患者能夠根據其獨特的基因譜獲得個人化的醫療解決方案，從而改善治療效果並提升患者滿意度。隨著消費者對個人化醫療的認知和需求不斷成長，保險與醫療保健的融合有望進一步推動市場發展，並使個人化醫療成為主流醫療模式。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 影響市場的因素
• 關鍵投資機會
• 生態系測繪
• 市場吸引力指數（2025）
• PESTEL 分析
• 技術分析
• 案例研究
• 專利分析
• 價值鏈分析
• 臨床試驗
• 貿易分析
• 原料分析
• Start-Ups分析
• 監管分析

全球個人化醫療市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 診斷
  • 基因檢測
  • DTC診斷
  • 專業檢驗服務
  • 特別檢查
  • 其他
• 治療藥物
  • 製藥
  • 基因組醫學
  • 醫療設備
  • 其他
• 個人化醫療
  • 遠端醫療
  • 健康資訊技術
  • 其他
• 個人化營養與健康
  • 零售營養
  • 補充和替代醫學
  • 其他

全球個人化醫療市場規模（依技術及複合年成長率分類）（2026-2033 年）

• 巨量資料分析
• 人工智慧
• 生物資訊學
• 基因定序
• 藥物發現
• 伴隨診斷
• 遺傳學
• 液態生物檢體
• 其他

全球個人化醫療市場規模（依給藥途徑分類）及複合年成長率（2026-2033 年）

• 院內個人化治療
• 居家檢測及治療
• 遠端醫療平台
• 即時診斷
• 其他

全球個人化醫療市場規模（按應用領域分類）及複合年成長率（2026-2033 年）

• 腫瘤學
• 中樞神經系統（CNS）
• 免疫學
• 呼吸系統
• 肝
• 風濕病學
• 其他

全球個人化醫療市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診斷中心
• 研究和學術機構
• 其他

全球個人化醫療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Illumina Inc.
• GE Healthcare
• Asuragen Inc.
• Abbott Laboratories
• Biogen Inc.
• Qiagen
• Thermo Fisher Scientific
• Novartis AG
• Pfizer Inc.
• Roche
• Foundation Medicine
• Cepheid
• Dako A/S
• NanoString Technologies
• Biocrates Life Sciences
• Precision Biologics
• Danaher Corporation
• Moderna
• Vertex Pharmaceuticals
• BioNTech

結論與建議

Global Personalized Medicines Market size was valued at USD 560.49 Billion in 2024 and is poised to grow from USD 612.62 Billion in 2025 to USD 1247.81 Billion by 2033, growing at a CAGR of 9.3% during the forecast period (2026-2033).

The personalized medicine market is experiencing significant growth as it integrates genetic technology to deliver tailored treatments for individual patients. Given the uniqueness of human genomes, diseases manifest differently across individuals, prompting a rising demand for personalized diagnostics and therapies, particularly in oncology. However, interest in non-oncology applications is also surging due to advancements in genetic technology, which is expanding rapidly. Investment in this sector continues to rise, fostering innovations that enhance personalized medicine's potential for treating rare diseases. Research efforts are intensifying around leveraging personalized approaches for conditions like Alzheimer's and Parkinson's disease. With increasing healthcare budgets and strengthened partnerships between pharmaceutical firms and government entities, the demand for personalized medicine is anticipated to accelerate further.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Personalized Medicines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Personalized Medicines Market Segments Analysis

Global Personalized Medicines Market is segmented by Product, Technology, Mode of Delivery, Application, End-user and region. Based on Product, the market is segmented into Diagnostics, Therapeutics, Personalized Medical Care and Personalized Nutrition and Wellness. Based on Technology, the market is segmented into Big Data Analytics, Artificial Intelligence, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Genetics, Liquid Biopsy and Others. Based on Mode of Delivery, the market is segmented into In-Hospital Personalized Treatment, Home-Based Testing & Treatment, Telemedicine Platforms, Point-of-Care Diagnostics and Others. Based on Application, the market is segmented into Oncology, CNS, Immunology, Respiratory, Liver, Rhematology and Others. Based on End-user, the market is segmented into Hospitals, Diagnostic Centers, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Personalized Medicines Market

The Global Personalized Medicines market is significantly driven by the rapid advancement of genetic technology, which is revolutionizing the healthcare and pharmaceutical industries. The increasing valuation of genetic technology, currently exceeding $5 billion, demonstrates robust demand and is attracting substantial investments annually. As the technology continues to progress, it is anticipated that the market will experience remarkable growth, with projections indicating a compound annual growth rate surpassing 20%. This surge in genetic technology will enhance the accessibility and demand for personalized medicines, fostering a wider adoption and implementation of tailored healthcare solutions for patients worldwide.

Restraints in the Global Personalized Medicines Market

Although healthcare infrastructure is advancing worldwide, the associated expenses are also escalating, often transferring the financial burden to consumers. The rising cost of healthcare outpaces inflation in many regions, leading to a decrease in demand for pricier personalized medicines. This trend poses a significant challenge to the Global Personalized Medicines market, as individuals may be reluctant to invest in these innovative treatments due to their elevated prices. Consequently, the financial constraints experienced by patients can hinder market growth and limit access to potentially life-saving personalized therapies, creating a significant restraint in the sector.

Market Trends of the Global Personalized Medicines Market

The Global Personalized Medicines market is experiencing a notable shift driven by the expansion of health insurance coverage, particularly in emerging economies. This evolution is facilitating greater accessibility and affordability of personalized therapies, as an increasing number of insurance providers are incorporating these advanced treatments into their policies. Enhanced insurance offerings are enabling more patients to receive tailored healthcare solutions based on their unique genetic profiles, leading to improved treatment outcomes and satisfaction. As consumer awareness and demand for personalized medicine rise, the convergence of insurance and healthcare is set to propel the market forward, making personalized treatments more mainstream.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Technology Analysis
• Case Studies
• Patent Analysis
• Value Chain Analysis
• Clinical Trials
• Trade Analysis
• Raw Material Analysis
• Startup Analysis
• Regulatory Analysis

Global Personalized Medicines Market Size by Product & CAGR (2026-2033)

• Market Overview
• Diagnostics
  • Genetic Testing
  • DTC Diagnostics
  • Esoteric Lab Services
  • Esoteric Lab Tests
  • Others
• Therapeutics
  • Pharmaceutical
  • Genomic Medicine
  • Medical Devices
  • Others
• Personalized Medical Care
  • Telemedicine
  • Health Information Technology
  • Others
• Personalized Nutrition and Wellness
  • Retail Nutrition
  • Complementary & Alternative Medicine
  • Others

Global Personalized Medicines Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Big Data Analytics
• Artificial Intelligence
• Bioinformatics
• Gene Sequencing
• Drug Discovery
• Companion Diagnostics
• Genetics
• Liquid Biopsy
• Others

Global Personalized Medicines Market Size by Mode of Delivery & CAGR (2026-2033)

• Market Overview
• In-Hospital Personalized Treatment
• Home-Based Testing & Treatment
• Telemedicine Platforms
• Point-of-Care Diagnostics
• Others

Global Personalized Medicines Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• CNS
• Immunology
• Respiratory
• Liver
• Rhematology
• Others

Global Personalized Medicines Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others

Global Personalized Medicines Market Size & CAGR (2026-2033)

• North America (Product, Technology, Mode of Delivery, Application, End-user)
  • US
  • Canada
• Europe (Product, Technology, Mode of Delivery, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Mode of Delivery, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Mode of Delivery, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Mode of Delivery, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asuragen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dako A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocrates Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations